S'abonner

Surgical site infection in hip arthroplasty in a 10-year follow-up prospective study: Risk and factors associated - 18/11/20

Doi : 10.1016/j.ajic.2020.05.021 
Ana Isabel Hijas-Gómez, MD, MPH, PhD a, , Antonio Checa-García, MD, PhD b, Álvaro López-Hualda, MD, PhD b, Homid Fahandezh-Saddi, MD, PhD b, Javier Martínez-Martín, MD, PhD b, Mario Gil-Conesa, MD, MPH c, Diego Rodríguez-Villar, MD d, Ángel Gil-de-Miguel, MD, MPH, PhD d, Gil Rodríguez-Caravaca, MD, MPH, PhD c, d
a Health Technology Assessment Agency (AETS), Carlos III Institute of Health, Madrid, Spain 
b Department of Orthopedic Surgery and Traumatology, University Hospital Fundación Alcorcón, Madrid, Spain 
c Department of Preventive Medicine and Public Health, University Hospital Fundación Alcorcón, Madrid, Spain 
d Department of Preventive Medicine and Public Health, University Rey Juan Carlos, Madrid, Spain 

Address correspondence to Ana Isabel Hijas-Gómez, MD, MPH, PhD, Health Technology Assessment Agency (AETS), Carlos III Institute of Health, Madrid, Spain.Health Technology Assessment Agency (AETS)Carlos III Institute of HealthMadridSpain

Highlights

The increased demand for hip arthroplasty means a growing number of postsurgical complications.
Surgical site infection is the second most frequent complication after prosthetic loosening.
Hospital-based infection surveillance is an important component for of surgical site infection control.
Timing of surgery (elective or urgent/unplanned) influences the infection risk in orthopedic surgery.
Operative times, blood transfusion or patient preparation before surgery, are key for infection prevention.

Le texte complet de cet article est disponible en PDF.

Résumé

Background

The increased demand for hip arthroplasty means a growing number of postsurgical complications. This study aims to assess the risk of surgical site infection (SSI) in a teaching hospital; develop regional, national and international external comparisons; and evaluate SSI-related risk factors, particularly according to the timing of surgery (urgent/unplanned or elective).

Methods

Prospective cohort study from January 2008 to December 2018. Patients were followed up to 90 days after surgery. Primary endpoint was SSI incidence according to the Centers for Disease Control and Prevention criteria. Multivariate analysis was conducted to find independently associated SSI risk factors. The association between risk factors and SSI incidence was assessed by reference to odds ratio (OR). Analyses were also performed among urgent/unplanned and elective patients to identify whether SSI risk factors differed between groups.

Results

The study population (n = 1,808) has an overall SSI rate of 3.0% (95% confidence interval [CI]: 2.4-3.9). Timing of surgery caused an effect modification, so surgery duration> 75th percentile (OR: 3.8; 95% CI: 1.5-9.8) and inadequate preparation (OR: 3.3; 95% CI: 1.1-10.0) were independent risk factors in the urgent/unplanned group; National Healthcare Safety Network risk index≥ 2 (OR: 6.3; 95% CI: 0.1-19.2) and transfusion (OR: 3.6; 95% CI: 1.1-11.9) in the elective group.

Conclusions

Hospital infection surveillance systems allow identifying risk factors susceptible to change. Characterization of factors that caused an effect modification is key to identify areas of quality improvement, including reducing operating times, preventing perioperative blood transfusion, or improving patient preparation before surgery.

Le texte complet de cet article est disponible en PDF.

Key Words : Hip replacement arthroplasty, Surgical wound infection, Cohort study, Infection control, Risk factor


Plan


 Financial support: The authors thank the European Regional Development Fund (ERDF) and the Health Research Fund (Fondo de Investigación Sanitaria/FIS) supporting the research projects PI11/01272 and PI14/01136 which enabled the completion of this study.
 The study was approved by the center Ethics Committee and Research Board.
 Potential conflicts of interest: All authors report no conflicts of interest relevant to this article.


© 2020  Association for Professionals in Infection Control and Epidemiology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 48 - N° 12

P. 1437-1444 - décembre 2020 Retour au numéro
Article précédent Article précédent
  • Clostridioides difficile infections in Alberta: The validity of administrative data using ICD-10 diagnostic codes for CDI surveillance versus clinical infection surveillance
  • Ted Pfister, Elissa Rennert-May, Jennifer Ellison, Kathryn Bush, Jenine Leal
| Article suivant Article suivant
  • SARS-CoV-2 infection and COVID-19: The lived experience and perceptions of patients in isolation and care in an Australian healthcare setting
  • Ramon Z. Shaban, Shizar Nahidi, Cristina Sotomayor-Castillo, Cecilia Li, Nicole Gilroy, Matthew V.N. O'Sullivan, Tania C. Sorrell, Elizabeth White, Kate Hackett, Shopna Bag

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.